DailyIQ
Last updated2 minutes ago

VTRS·Viatris Inc.

$17.25
-0.29 (-1.65%)
Overnight$17.25+0.00 (+0.00%)
High
$17.69
Open
$17.66
Market Cap
19.92B
52W High
$18.43
Low
$17.20
P. Close
$17.25
P/E
-
52W Low
$9.79
Fwd P/E
6.45
DailyIQ Est.
$20.52
Inst. Ownership
47.3%
Short Interest
3.64%
Days to Cover
4.2
Div. Yield
2.78%
Next Ex-Div
~Nov 20
NewEarnings release, scored · filed Aug 6, 2026Guidance raised · tone -3.7 vs prior release · 73 lines scoredSee the breakdown
Technical Score (1D)
86
BULLISH
News Sentiment
70
BULLISH
VTRS is a momentum leader on the 1D chart: a Technical Score of 86 with strong momentum and strong trend strength. The score ranks stocks against each other, so a reading this high says Viatris Inc. has been one of the stronger performers in the universe, not that it is overbought. Sentiment at 70 is aligned with that strength. $16.98 is the level to watch on any dip, and $18.93 is the next upside reference beyond $18.40. DailyIQ's indicator breakdown shows how individual readings such as RSI (neutral range) and MACD (bullish) look right now. Those readings are context only and do not feed the Technical Score, which ranks VTRS's momentum against the rest of the universe.
LOW TARGET
$13 -24.6%
2 analysts
MEAN TARGET
$20 +14.2%
9 analysts
HIGH TARGET
$26 +50.7%
7 analysts
PRICE RANGE
$13.00 - $26.00
SB / B / H / S / SS
4/7/5/1/1
DAILYIQ EST.
$20.52 (+19.0%)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NMS
Country
United States
Symbol
VTRS
Description
Viatris Inc. is a global healthcare company focused on providing a diverse portfolio of medicines across various therapeutic areas. The company's core business revolves around the development, manufacturing, and distribution of prescription brand drugs, generic drugs, complex generics, and biosimilars. Viatris serves a broad range of markets, including North America, Europe, China, and emerging markets, offering products in areas such as cardiovascular health, oncology, and respiratory care. Its value proposition lies in its extensive product offerings, encompassing oral solid doses, injectables, and complex formulations, which are distributed through multiple channels to reach patients worldwide. Strategic collaborations with other pharmaceutical companies further enhance its product pipeline and market reach, solidifying its position in the competitive healthcare landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
61,442 shares
$994K
SIMMONS DAVID S-
Award/Grant2,117 shares2026-09-30
Groothuis Leo Frans-
Award/Grant2,469 shares2026-09-30
Enrietti AndrewSee Remarks
Option Exercise998.364 shares2026-08-15
Enrietti AndrewSee Remarks
Option Exercise25,134 shares2026-08-15
Enrietti AndrewSee Remarks
Tax Withholding435 shares2026-08-15
46/ 100
Neutral / mixed
Overall: Neutral
✕Revenue declining year over year
✕Negative net margin
✓Positive operating cash flow
Gross Margin
35.2%
Net Margin
-24.7%
Revenue CAGR
3.4%
Current Ratio
1.38x
Debt / Equity
0.98x
Return on Equity
-23.9%
Earnings Summary
Viatris Inc. is a global healthcare company that develops, manufactures, and distributes a broad portfolio of prescription brand drugs, generics, complex generics, and biosimilars across North America, Europe, China, and emerging markets, positioning it within the specialty and generic drug manufacturing sector. In the most recent quarters, Viatris reported Q4 2025 revenue of $3.70 billion, up from $3.58 billion in Q3 2025, and Q1 2026 revenue of $3.52 billion, slightly down from $3.58 billion in Q4 2025; EPS in Q4 2025 was $0.57 versus $0.62 in Q2 2025, and Q1 2026 EPS was $0.59 versus $0.69 in Q2 2026, indicating a modest deceleration in earnings growth while revenue growth remained relatively flat. Historically, the company has shown a steady YoY revenue increase of roughly 5–7% over the past four quarters, with EPS beating estimates in three of the last four quarters (Q2 2025, Q3 2025, Q4 2025) but missing in Q1 2026, reflecting a pattern of strong revenue performance even when earnings lag slightly behind analyst expectations. Recent news highlights the completion of a $1.65 billion all‑cash acquisition of Pacira BioSciences on October 8, adding the non‑opioid pain products Exparel and Zilretta, which generated $692 million in 2025 sales, to Viatris’s portfolio; this strategic move is expected to broaden its therapeutic reach and potentially lift margin profiles, a development that may influence future earnings dynamics.

EPS

EstBeatMiss
$0.53$0.58$0.62$0.67$0.71Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.64 - -
Q2'26$0.61$0.69+12.6%
Q1'26$0.61$0.59-3.4%
Q4'25$0.55$0.57+3.4%
Q3'25$0.62$0.67+8.5%
Q2'25$0.56$0.62+11.6%

Revenue

EstBeatMiss
$3.3B$3.4B$3.6B$3.8B$4.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.9B - -
Q2'26$3.8B$3.8B+0.1%
Q1'26$3.4B$3.5B+2.7%
Q4'25$3.3B$3.7B+10.7%
Q3'25 - $3.8B -
Q2'25 - $3.6B -

Market Data

VTRS Stock Snapshot

BULLISH86/100
$17.25+$0.00 (0.0%)
Market cap
19.92B
Day range
$17.20 – $17.69
News sentiment
70/100 · Bullish
Analyst target
$19.70 (+14.2%)
Consensus
Buy · 18 analysts
52-week range+76.2% off low · -6.4% from high
$9.79$18.43
Price $17.25 DailyIQ Est. $20.52

The signal on VTRS is bullish: price action is confirming the underlying trend, not fighting it. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into VTRS?

CHEAP

At today's price, Viatris Inc. needs to grow free cash flow about -6.1% a year for the next 10 years to justify its valuation at a 6.60% cost of capital. Over its actual history it has compounded free cash flow at 3.9% a year, so the market is asking for 10.0 percentage points below its own delivered rate. On that basis VTRS looks priced below what its own growth record supports.

Implied FCF growth
-6.1%
Historical FCF CAGR
3.9%
Growth gap
-10.0 pts
Verdict
CHEAP
Discount rate (WACC)
6.60%
Beta
0.80

Behaviour On Record

What VTRS's own history says about today's numbers

Realized volatility (21d)
23.8% 20th pct
Below its peak
-77.2%
vs 200-day average
+11.4%
Up days (1y)
54%

Viatris Inc. is currently running 23.8% annualised volatility over the last 21 sessions. Measured against VTRS's own 13 years of daily returns rather than a market-wide average, that is the 20th percentile — unusually subdued by its own history, against a typical reading of 30.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

VTRS is trading -77.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -39.1%, and the deepest was -48.1% in 2015. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +11.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 84th percentile — a wider gap than this stock usually carries. Over the past year VTRS closed higher on 54% of sessions, and it is currently 2 sessions into a falling streak.

On October specifically: over 13 years of records, VTRS finished the month higher 7 of 13 times, with a median return of +0.7% and an average of +1.4%. Its strongest month historically has been November at +4.9% on average, its weakest March at -5.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: VTRS has opened more than 2% away from the prior close in 148 of 3,267 sessions (4.5% of the time), with the largest gaps running +9.8% and -5.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, VTRS moved an average of 1.5% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.5% and a largest of -2.0%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against VTRS's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of VTRS's sector?

Viatris Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 12
Sector state
Improving
Sector rotation score
64

Options Market

What is the options market pricing for VTRS?

CallsPuts

For Viatris Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.30), with at-the-money implied volatility around 6.3%. The options market is pricing roughly a ±0.5% move by that expiry — a range of about $17.28–$17.44.

Put/call ratio (2026-10-16)
0.30
ATM implied volatility
6.3%
Total open interest
15,170
Expected move by 2026-10-16
±0.5% ($17.28–$17.44)

Analyst Rating Changes

Are analysts turning bullish or bearish on VTRS?

UBS most recently reiterated its rating on Viatris Inc. to Buy on Oct 5, 2026 with a price target of $26 (from $23). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBS — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 5, 2026UBSMaintainedBuy$23 → $26
Sep 23, 2026OppenheimerInitiatedOutperform$25
Sep 16, 2026Piper SandlerMaintainedNeutral$12 → $13
Sep 9, 2026Leerink PartnersInitiatedOutperform$20
Sep 8, 2026Argus ResearchMaintainedBuy$15 → $20
May 19, 2026BarclaysMaintainedOverweight$17 → $22
May 8, 2026JP MorganMaintainedNeutral$17 → $18
May 8, 2026Truist SecuritiesMaintainedBuy$18 → $20
Mar 24, 2026BarclaysMaintainedOverweight$15 → $17
Jan 28, 2026Piper SandlerMaintainedNeutral$9 → $12
Jan 16, 2026Argus ResearchUpgradeHold → Buy$15
Dec 9, 2025BarclaysInitiatedOverweight$15

Earnings Release, Scored

What did Viatris Inc.'s latest earnings release say?

Filed Aug 6, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone62.1/ 100-3.7 vs prior release
Hedging words1.79per 100 words+0.42 vs prior release
Tone, last 2 releasesScale 50–71

Most important lines

  1. 1

    Our strong first-half results give us the confidence to raise our full-year guidance.

    Guidance raisedNew this quarter
  2. 2

    In August, the Company signed a definitive agreement to sell the global product rights for Tyrvaya to Harrow, Inc., a leading provider of ophthalmic disease management solutions in North America, for an upfront payment of $30 million and an additional $70 million in commercial contingent milestone payments.

    New this quarter
  3. 3

    The loss in the second quarter of 2026 was primarily driven by a non-cash charge of $177.8 million related to the planned sale of the product rights for Tyrvaya ® and the write down of that intangible asset to fair value, less cost to sell.

    New this quarter

Peers & ETF holders

VTRS peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

70/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Viatris posted a 50% year‑to‑date gain, driven by renewed growth and improved operating leverage after a period of stagnation and execution challenges. The company’s management reiterated confidence in its strategic direction, citing a return to profitability and a focus on M&A activity. Analysts noted that the rebound reflects a solid turnaround, though they maintained a hold recommendation, suggesting that the upside is moderate and not yet fully priced in.
What did this article say?
On October 9, Viatris announced a $1.65 billion cash purchase of Pacira BioSciences, paying a 45% premium to Pacira’s closing price. The deal adds Pacira’s Exparel and Zilretta products to Viatris’s branded‑medicine lineup, targeting the pain‑management market. Viatris expects the acquisition to strengthen its U.S. presence and accelerate growth of its non‑opioid pain drug pipeline. The transaction reflects a strategic shift toward high‑margin specialty drugs rather than experimental candidates.
What did this article say?
Viatris announced a definitive agreement to acquire Pacira BioSciences for $1.65 billion in cash, adding two marketed pain therapies and a clinical‑stage gene therapy candidate to its portfolio. The deal is expected to strengthen Viatris’ position in non‑opioid pain management and broaden its specialty pain care offerings. Both boards approved the transaction, and completion will depend on customary closing conditions, including a tender offer for Pacira shares.
What did this article say?
Viatris announced a $1.65 billion acquisition of Pacira BioSciences to strengthen its pain‑management portfolio and counter revenue stagnation. The deal is expected to be immediately accretive, leveraging VTRS’s global sales infrastructure to boost sales of Pacira’s high‑margin, patent‑protected products. While the acquisition signals strategic growth, analysts noted execution risks and ongoing legacy revenue declines that could temper upside.
What did this article say?
On October 9, Viatris announced a $1.65 billion all‑cash acquisition of Pacira BioSciences, adding two patent‑protected non‑opioid pain medicines to its product lineup. The deal is expected to broaden Viatris’ therapeutic reach and strengthen its revenue base in the pain management segment. Analysts view the transaction as a strategic move that could enhance long‑term earnings and support future growth initiatives.
What did this article say?
Viatris Inc. awaited FDA approval of MR‑141, an eye drop for presbyopia, scheduled for decision on October 17. The drug, already sold as Ryzumvi for pupil dilation, would represent a label expansion rather than a new molecule. Approval would add a margin‑friendly branded product to Viatris’ portfolio, supporting its shift from generics to higher‑margin medicines. The company’s global sales force would promote the product worldwide under a 2022 partnership with Opus Genetics. The potential upside is modest but aligns with Viatris’ strategic focus on branded growth.
What did this article say?
Viatris agreed to acquire Pacira BioSciences in an all‑cash transaction valued at approximately $1.65 billion, aiming to broaden its non‑opioid pain‑management lineup. The deal was announced during a broader sector sell‑off that saw the NYSE Healthcare Index decline 0.6 %. Pacira shares surged 44 % following the news, while Viatris shares fell 0.7 % amid market volatility. The acquisition is expected to strengthen Viatris’ position in post‑surgical and acute pain treatment without relying on opioids.
What did this article say?
Viatris announced on October 8 that it would acquire Pacira BioSciences for $1.65 billion, valuing the target at $36.50 per share. The transaction represents a roughly 45% premium over Pacira’s recent trading price and is expected to close by the end of 2026. The deal expands Viatris’ portfolio in specialty pharmaceuticals and enhances its presence in the U.S. market. The acquisition is viewed as a strategic move to strengthen Viatris’ growth trajectory and diversify its product offerings.
What did this article say?
Viatris announced an all‑cash purchase of Pacira BioSciences for roughly $1.65 billion, a move that was highlighted among the top midday gainers. The announcement led to a 44 % intraday spike in Pacira stock, with trading volume soaring to over 24 million shares. Viatris shares experienced a modest decline of 0.7 % amid broader market movements. The transaction is viewed as a strategic expansion of Viatris’ non‑opioid pain‑management portfolio.

Technical Analysis

Real-time indicators across multiple timeframes

86
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $8.14B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell138,179,86411.96%$1.72B2026-01-29
FMR LLC (Fidelity)▲ Buy96,662,1028.37%$1.53B2026-08-13
BlackRock, Inc.▲ Buy86,019,4687.45%$1.37B2026-08-07
Davis Selected Advisers▼ Sell75,232,2546.51%$1.19B2026-08-11
Geode Capital Management, LLC▲ Buy32,807,9062.84%$520.10M2026-08-12
Invesco Ltd.▼ Sell20,771,2751.80%$329.85M2026-08-14
Morgan Stanley▼ Sell15,128,8991.31%$240.25M2026-08-13
Goldman Sachs Group Inc▼ Sell13,564,8721.17%$215.41M2026-08-14
Northern Trust Corp▼ Sell10,038,6910.87%$159.41M2026-08-13
Glenview Capital Management, LLC▲ Buy9,877,4090.86%$156.85M2026-08-14
JPMorgan Chase & Co▲ Buy7,322,2670.63%$119.69M2026-08-12
Bank of America Corp▲ Buy7,356,7080.64%$116.82M2026-08-14
AQR Capital Management LLC▼ Sell4,694,9660.41%$74.56M2026-08-14
Gotham Asset Management, LLC▼ Sell4,374,6830.38%$69.47M2026-08-14
Citigroup Inc▲ Buy4,360,4440.38%$69.24M2026-08-03
Norges Bank▼ Sell3,822,7440.33%$60.71M2026-08-12
Man Group plc▼ Sell3,523,0520.31%$55.95M2026-08-14
Bridgewater Associates, LP▲ Buy1,698,3410.15%$26.97M2026-08-14
Moore Capital Management, LP▲ Buy1,430,6540.12%$22.72M2026-08-14
Wells Fargo & Company▲ Buy1,175,4950.10%$18.67M2026-08-14
AllianceBernstein L.P.▲ Buy1,233,2340.11%$16.66M2026-08-14
Prudential Financial Inc▲ Buy849,6940.07%$13.49M2026-08-12
Adage Capital Partners GP, L.L.C.▲ Buy843,7360.07%$13.40M2026-08-14
Marshall Wace, LLP▼ Sell839,8200.07%$13.34M2026-08-13
D. E. Shaw & Co., Inc.▼ Sell791,3710.07%$12.57M2026-08-14
Q2 2026 flow:87.79M sh bought ($1.39B)22.26M sh sold ($353.43M)net +65.53M sh (+$1.04B)
Congressional Trading Activity
6 disclosed trades · ~$48.0K est. traded value · 2 buys, 4 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-03-312025-04-07
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-08-012022-09-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2022-01-132022-02-14